ES2446306T3 - Uso de un inhibidor de psd-95 tratamiento para la epilepsia - Google Patents

Uso de un inhibidor de psd-95 tratamiento para la epilepsia Download PDF

Info

Publication number
ES2446306T3
ES2446306T3 ES09747499.3T ES09747499T ES2446306T3 ES 2446306 T3 ES2446306 T3 ES 2446306T3 ES 09747499 T ES09747499 T ES 09747499T ES 2446306 T3 ES2446306 T3 ES 2446306T3
Authority
ES
Spain
Prior art keywords
epilepsy
inhibitor
peptide
episode
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09747499.3T
Other languages
English (en)
Spanish (es)
Inventor
James Gurd
Crystal Dykstra
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Application granted granted Critical
Publication of ES2446306T3 publication Critical patent/ES2446306T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09747499.3T 2008-05-16 2009-05-13 Uso de un inhibidor de psd-95 tratamiento para la epilepsia Active ES2446306T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5410908P 2008-05-16 2008-05-16
US54109P 2008-05-16
PCT/US2009/043831 WO2009140416A2 (en) 2008-05-16 2009-05-13 Treatment for epilepsy

Publications (1)

Publication Number Publication Date
ES2446306T3 true ES2446306T3 (es) 2014-03-07

Family

ID=41319319

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09747499.3T Active ES2446306T3 (es) 2008-05-16 2009-05-13 Uso de un inhibidor de psd-95 tratamiento para la epilepsia

Country Status (9)

Country Link
US (1) US9161965B2 (https=)
EP (1) EP2307035B1 (https=)
JP (2) JP6005357B2 (https=)
CN (1) CN102088990A (https=)
AU (1) AU2009246316B2 (https=)
CA (1) CA2724483C (https=)
DK (1) DK2307035T3 (https=)
ES (1) ES2446306T3 (https=)
WO (1) WO2009140416A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
US20140323924A1 (en) * 2013-04-26 2014-10-30 David J. Mishelevich Targeted optogenetic neuromodulation for treatment of clinical conditions
EP2950715A4 (en) * 2013-01-31 2016-11-30 Univ California SYSTEM AND METHOD FOR MODELING BRAIN DYNAMICS IN NORMAL AND ILLNESS STATES
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
US10583171B2 (en) 2015-11-30 2020-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) NMDAR antagonists for the treatment of diseases associated with angiogenesis
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
KR20250048151A (ko) * 2016-12-09 2025-04-07 알렉스자 파마스티칼즈, 인크. 간질 치료 방법
BR112020000115A2 (pt) 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) * 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CN111712252A (zh) 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
EP3856212A1 (en) * 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
US20210137853A1 (en) * 2019-09-17 2021-05-13 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US20050019841A1 (en) 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US20050282743A1 (en) 2001-08-03 2005-12-22 Arbor Vita Corporation Molecular interactions in cells
US20090075377A1 (en) 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005097090A2 (en) * 2004-04-05 2005-10-20 Icos Corporation AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
CA2641421C (en) * 2005-12-30 2014-07-29 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8633160B2 (en) 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN102088990A (zh) 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法

Also Published As

Publication number Publication date
US20100160240A1 (en) 2010-06-24
WO2009140416A2 (en) 2009-11-19
DK2307035T3 (da) 2014-01-20
AU2009246316A1 (en) 2009-11-19
CA2724483C (en) 2018-01-02
CN102088990A (zh) 2011-06-08
JP6005357B2 (ja) 2016-10-12
US9161965B2 (en) 2015-10-20
EP2307035A4 (en) 2012-04-11
EP2307035B1 (en) 2013-12-04
EP2307035A2 (en) 2011-04-13
AU2009246316B2 (en) 2014-06-19
WO2009140416A3 (en) 2010-01-14
JP2011520900A (ja) 2011-07-21
CA2724483A1 (en) 2009-11-19
JP2016199553A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
ES2446306T3 (es) Uso de un inhibidor de psd-95 tratamiento para la epilepsia
ES2555172T3 (es) Péptidos inhibidores de receptores NMDA para uso en en tratamiento de trastornos de la ansiedad
ES2902467T3 (es) TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento
Wemmie et al. Acid-sensing ion channels in pain and disease
ES2273849T3 (es) Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta.
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
ES2765281T3 (es) Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
ES2397637T3 (es) Inhibidores de PAK para uso en el tratamiento de trastornos del desarrollo neurológico
ES2404940T3 (es) Reactivos de peptoide específicos para prión
CA2833515A1 (en) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
ES2869300T3 (es) Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
ES2247329T3 (es) Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales.
ES2434943T3 (es) Uso de antagonista de bombesina/péptido liberador de gastrina para el tratamiento de septicemia, choque séptico, lesión pulmonar aguda o artritis reumatoide